Estrella Immunopharma, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 0.7287 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 31.70M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company’s lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It offers ARTEMIS, a cell receptor platform to develop and commercialize T-cell therapies targeting CD19 and CD22 for the treatment of hematologic malignancies. It has a collaborative agreement with Eureka and Imugene Limited for the development of solid tumor treatments using Imugene’s product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California. Estrella Immunopharma, Inc. is a subsidiary of Eureka Therapeutics, Inc.
Details
| Name | Estrella Immunopharma, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Founded | 2021 |
| Ceo | Cheng Liu |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US2975841048 |
| Cusip | 297584104 |
| Cik | 1844417 |
| Sic | 2836 |
Key executives
| Name | Title |
|---|---|
| Dr. Cheng Liu Ph.D. | Chief Executive Officer, President and Director |
| Jiandong Xu | Chief Financial Officer |
Contact
| Address | 5858 Horton Street, Suite 370, EmeryVille, California 94608, United States |
| Phone | 510 318 9098 |
| Website | https://www.estrellabio.com |